StreetInsider.com News Articles

Senti Biosciences (SNTI) files for 15.97M share offering by selling stockholders

Thu, 16 Jul 2026 06:08:19 -0400

Senti Biosciences (NASDAQ: SNTI) has filed for up to 15,971,890 share offering by selling stockholders.

Senti Biosciences (SNTI) files for 15.97M share offering by selling stockholders

Thu, 16 Jul 2026 06:08:19 -0400

Senti Biosciences (NASDAQ: SNTI) has filed for up to 15,971,890 share offering by selling stockholders.

Senti Biosciences to spin off SENTI-202 unit in CVR deal

Wed, 15 Jul 2026 07:30:56 -0400

Senti Biosciences Holdings, Inc. (NASDAQ: SNTI) announced a transaction in which it will transfer its Gene-Circuit-enabled pipeline, including the SENTI-202 therapy, to a newly formed private biotechnology company controlled by affiliates of Celadon, the company's largest investor.

In exchange, Senti Biosciences Holdings will receive a contingent value right (CVR) that provides its equity holders with potential milestone payments of up to $60 million over seven years, structured as follows:

$10 million upon filing and acceptance of a Biologics License Application (BLA) for SENTI-202
$20 million upon FDA approval of a BLA for SENTI-202
$30 million upon achievement of $200 million in cumulative net sales

Senti Biosciences to spin off SENTI-202 unit in CVR deal

Wed, 15 Jul 2026 07:30:56 -0400

$10 million upon filing and acceptance of a Biologics License Application (BLA) for SENTI-202
$20 million upon FDA approval of a BLA for SENTI-202
$30 million upon achievement of $200 million in cumulative net sales

Senti Biosciences to spin off SENTI-202 unit in CVR deal

Wed, 15 Jul 2026 07:30:56 -0400

$10 million upon filing and acceptance of a Biologics License Application (BLA) for SENTI-202
$20 million upon FDA approval of a BLA for SENTI-202
$30 million upon achievement of $200 million in cumulative net sales

Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable

Wed, 15 Jul 2026 07:30:00 -0400

Senti Biosciences Holdings, Inc. to Advance Controllable Cell and Gene Therapies Leveraging the Regulator Dial Platform™
Spin-off of Senti Biosciences, Inc., including SENTI-202, Aims to Unlock Value via Contingent Value Right to Potential Future Milestone Payments of up to $60 Million for Logic-Gated SENTI-202 Development and Commercialization

SOUTH SAN FRANCISCO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (NASDAQ: SNTI) (“SBH” or the “Company”) today announced a strategic transaction designed to sharpen its focus on next-generation controllable genetic medicines powered by its Regulator Dial™ technology platform (the “Retained Assets”) and unlock value for

Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable

Wed, 15 Jul 2026 07:30:00 -0400

Senti Biosciences Holdings, Inc. to Advance Controllable Cell and Gene Therapies Leveraging the Regulator Dial Platform™
Spin-off of Senti Biosciences, Inc., including SENTI-202, Aims to Unlock Value via Contingent Value Right to Potential Future Milestone Payments of up to $60 Million for Logic-Gated SENTI-202 Development and Commercialization

Radoff-JEC Group pushes for board change at Seer, Inc.

Mon, 29 Jun 2026 16:11:09 -0400

The Radoff-JEC Group, which holds approximately 7.7% of shares in Seer, Inc. (NASDAQ: SEER), has released a presentation calling for stockholders to replace three board members at the company's annual meeting scheduled for July 28, 2026.

The group, composed of Bradley L. Radoff and Michael Torok along with certain affiliates, is urging stockholders to vote against Chair and CEO Omid Farokhzad, M.D., Compensation Committee Chair Terrance McGuire, and Director Deep Nishar. In their place, the group is nominating Howard H. Berman, Ph.D., Joshua S. Horowitz, and Luis E. Rinaldini.

According to the presentation, Seer's share price has declined 97% from December 4,

Radoff-JEC Group pushes for board change at Seer, Inc.

Mon, 29 Jun 2026 16:11:09 -0400

According to the presentation, Seer's share price has declined 97% from December 4,

Radoff-JEC Group pushes for board change at Seer, Inc.

Mon, 29 Jun 2026 16:11:09 -0400

According to the presentation, Seer's share price has declined 97% from December 4,

Radoff-JEC Group pushes for board change at Seer, Inc.

Mon, 29 Jun 2026 16:11:09 -0400

According to the presentation, Seer's share price has declined 97% from December 4,

The Radoff-JEC Group Releases Presentation Highlighting Why Seer, Inc. Stockholders Should Vote for Boardroom Change

Mon, 29 Jun 2026 16:10:00 -0400

Details How Chair and CEO Omid Farokhzad, M.D., Compensation Committee Chair Terrance McGuire and Director Deep Nishar Have Burned More Than $310 Million in Cash, Adopted an Anti-Stockholder Poison Pill and Paid Themselves Excessively While Overseeing a 97% Decline in Seer’s Share Price